Trior Raises $25 Million in Series C for ADC Platforms

By Olivia Hart

Trior raised USD 25 million (33 billion won) in a Series C round, according to Wowtale. The same report said the financing lifted cumulative funding to USD 58 million (77 billion won). Using the headline figures, the round represents about 43% of Trior’s cumulative capital.

“With this investment, we will accelerate the development of our core platforms and key pipelines, and expand commercialization opportunities such as collaboration and technology transfer with domestic and international biotech companies and global pharmaceutical firms,” said Seongho Woo, CEO of Trior.

Woo’s statement ties the financing to faster development and broader commercial opportunities. Wowtale’s report supplies no valuation, closing date, named drug candidates, development timetable or performance data supporting the platform claims.

Who backed the two closings?

According to Wowtale, Trior conducted the Series C as a multi-closing round with two tranches. The first close brought in USD 18 million (24 billion won), mainly from new investors. The second added USD 6.8 million (9 billion won), mainly from existing investors.

Wowtale identified new and existing participants as follows:

• New investors: Korea Development Bank, DS Asset Management, HB Investment, SAGE ONE PARTNERS and TESS Investment Partners.
• Existing investors: Woori Venture Partners, LSK Investment, Shinhan Capital and Sneak Peek Investments also made follow-on investments.
• Co-investment structure: Honeypot Ventures took part in the TESS Investment Partners investment as a co-general partner (Co-GP).

At the dollar precision used in the report, the two tranches total USD 24.8 million, USD 200,000 below the headline USD 25 million. Their won figures reconcile: 24 billion plus 9 billion equals the announced 33 billion won. Wowtale does not explain the dollar gap; rounding may account for it, but the source does not say so.

Korea Development Bank invested USD 9.1 million (12 billion won). DS Asset Management invested USD 3.8 million (5 billion won), using capital from the National Growth Fund.

Measured against the headline round, those investments equal about 36% and 15% of funding, respectively, or roughly 52% together. Wowtale provides no amounts for HB Investment, SAGE ONE PARTNERS, TESS Investment Partners or the four existing investors. The report also identifies no lead investor, valuation or equity stakes.

Takeaway: Trior added substantial capital and new backers, but the financing terms and full allocation remain undisclosed.

What are Trior’s two platforms?

According to Wowtale, Trior has two platforms for developing antibody therapeutics and ADCs. TROCAD uses dual-function masking with the stated aim of improving the therapeutic index of antibody-based therapies.

TROSIG is a linker-payload platform developed to improve drug stability and therapeutic efficacy of ADCs. Trior uses both platforms to develop its own antibody therapeutic and ADC drug pipelines.

The company is also pursuing joint R&D and technology transfer with domestic and international biotech companies and global pharmaceutical firms. Wowtale names no partners, drug candidates, trial phases or comparative performance data, leaving the platforms’ commercial reach unquantified.

Takeaway: Trior has two distinct development platforms, but the report offers no comparative performance data.

How will Trior use the money?

Trior plans to advance its core platform technologies and finance R&D on its main drug pipelines, Wowtale reported. The company also plans to move its lead pipeline through preclinical and clinical development and broaden the range of applications for its platforms.

Those objectives span platform work and drug development, but the announcement gives no program-level budgets or milestones. It does not identify the lead asset or specify its current stage, preclinical timing, clinical start date or continuation criteria.

Based on Wowtale’s figures, the USD 58 million total measures capital raised, not development risk resolved. The report omits a spending schedule and investor rights, so the funding cannot show how long Trior can operate without another raise.

The next checkpoint is execution: named assets, dated preclinical or clinical milestones, and signed collaboration or technology-transfer agreements. Without those disclosures, the financing shows capacity rather than commercial validation.

Takeaway: Named assets, dated milestones and signed partners would turn Trior’s platform claims into assessable commercial progress.